Drug profile · INN
tremelimumab-actl
IMJUDO
tremelimumab-actl (IMJUDO) is a cytotoxic t-lymphocyte protein 4 inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — tremelimumab-actl
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
tremelimumab-actl (IMJUDO) is a cytotoxic t-lymphocyte protein 4 inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Cytotoxic T-lymphocyte protein 4 inhibitor
Primary target: Cytotoxic T-lymphocyte protein 4
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Related & competitor drugs
Frequently asked questions
What is tremelimumab-actl?
tremelimumab-actl (IMJUDO) is a cytotoxic t-lymphocyte protein 4 inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for tremelimumab-actl?
IMJUDO is a marketed brand name for tremelimumab-actl. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tremelimumab-actl?
tremelimumab-actl has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.